|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C15orf61 |
Gene summary for C15ORF61 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C15orf61 | Gene ID | 145853 |
| Gene name | chromosome 15 open reading frame 61 | |
| Gene Alias | C15orf61 | |
| Cytomap | 15q23 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | A6NNL5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 145853 | C15orf61 | LZE2D | Human | Esophagus | HGIN | 3.16e-02 | 3.40e-01 | 0.0642 |
| 145853 | C15orf61 | LZE2T | Human | Esophagus | ESCC | 1.18e-02 | 5.91e-01 | 0.082 |
| 145853 | C15orf61 | LZE4T | Human | Esophagus | ESCC | 3.35e-14 | 4.24e-01 | 0.0811 |
| 145853 | C15orf61 | LZE5T | Human | Esophagus | ESCC | 4.40e-02 | 4.39e-01 | 0.0514 |
| 145853 | C15orf61 | LZE24T | Human | Esophagus | ESCC | 5.29e-14 | 3.55e-01 | 0.0596 |
| 145853 | C15orf61 | LZE21T | Human | Esophagus | ESCC | 1.22e-10 | 5.97e-01 | 0.0655 |
| 145853 | C15orf61 | P1T-E | Human | Esophagus | ESCC | 3.21e-18 | 9.90e-01 | 0.0875 |
| 145853 | C15orf61 | P2T-E | Human | Esophagus | ESCC | 2.77e-41 | 9.39e-01 | 0.1177 |
| 145853 | C15orf61 | P4T-E | Human | Esophagus | ESCC | 2.38e-49 | 1.29e+00 | 0.1323 |
| 145853 | C15orf61 | P5T-E | Human | Esophagus | ESCC | 1.32e-19 | 3.19e-01 | 0.1327 |
| 145853 | C15orf61 | P8T-E | Human | Esophagus | ESCC | 2.81e-41 | 6.24e-01 | 0.0889 |
| 145853 | C15orf61 | P9T-E | Human | Esophagus | ESCC | 2.43e-50 | 1.17e+00 | 0.1131 |
| 145853 | C15orf61 | P10T-E | Human | Esophagus | ESCC | 1.99e-68 | 1.16e+00 | 0.116 |
| 145853 | C15orf61 | P11T-E | Human | Esophagus | ESCC | 2.22e-09 | 7.57e-01 | 0.1426 |
| 145853 | C15orf61 | P12T-E | Human | Esophagus | ESCC | 8.46e-57 | 1.00e+00 | 0.1122 |
| 145853 | C15orf61 | P15T-E | Human | Esophagus | ESCC | 7.28e-56 | 1.22e+00 | 0.1149 |
| 145853 | C15orf61 | P16T-E | Human | Esophagus | ESCC | 2.81e-49 | 9.36e-01 | 0.1153 |
| 145853 | C15orf61 | P17T-E | Human | Esophagus | ESCC | 3.57e-06 | 3.24e-01 | 0.1278 |
| 145853 | C15orf61 | P19T-E | Human | Esophagus | ESCC | 1.23e-06 | 8.93e-01 | 0.1662 |
| 145853 | C15orf61 | P20T-E | Human | Esophagus | ESCC | 9.78e-42 | 8.08e-01 | 0.1124 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C15orf61 | SNV | Missense_Mutation | novel | c.278C>G | p.Ser93Cys | p.S93C | A6NNL5 | protein_coding | deleterious(0) | probably_damaging(0.948) | TCGA-E2-A9RU-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | arimidex | SD |
| C15orf61 | SNV | Missense_Mutation | c.460N>T | p.Gly154Cys | p.G154C | A6NNL5 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-G4-6304-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | PD | |
| C15orf61 | SNV | Missense_Mutation | novel | c.290N>T | p.Trp97Leu | p.W97L | A6NNL5 | protein_coding | tolerated(0.62) | benign(0.007) | TCGA-EY-A1GQ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | taxol | SD |
| C15orf61 | SNV | Missense_Mutation | novel | c.262A>G | p.Ile88Val | p.I88V | A6NNL5 | protein_coding | tolerated(0.14) | benign(0.006) | TCGA-PG-A917-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |